Skip to main content

ESTUDIO DE ALTERACIONES EN VIAS DE SEÑALIZACION DEL ENDOTELIO VASCULAR Y SU CORRELACION CLINICA EN LA TELANGIECTASIA HEMORRAGICA HEREDITARIA

PI17/00669

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2017
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION IDIBELL
Execution centre INSTITUTO DE INVESTIGACION BIOMEDICA DE BELLVITGE (IDIBELL)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

New genetic drivers in hemorrhagic hereditary telangiectasia

  • Cerdà, Pau|||0000-0003-4368-6260
  • Castillo, Sandra D.|||0000-0002-7007-3155
  • Aguilera, Cinthia|||0000-0002-0363-8590
  • Iriarte, Adriana
  • Rocamora, José Luis
  • Larrinaga, Ane M.
  • Viñals, Francesc|||0000-0002-9918-6751
  • Graupera, Mariona|||0000-0003-4608-4185
  • Riera Mestre, Antoni|||0000-0001-9411-804X
Background: Hereditary hemorrhagic telangiectasia (HHT) is a rare vascular disease inherited in an autosomal dominant manner. Disease-causing variants in endoglin (ENG) and activin A receptor type II-like 1 (ACVRL1) genes are detected in around 90% of the patients; also 2% of patients harbor pathogenic variants at SMAD4 and GDF2. Importantly, the genetic cause of 8% of patients with clinical HHT remains unknown. Here, we present new putative genetic drivers of HHT. Methods: To identify new HHT genetic drivers, we performed exome sequencing of 19 HHT patients and relatives with unknown HHT genetic etiology. We applied a multistep filtration strategy to catalog deleterious variants and prioritize gene candidates based on their known relevance in endothelial cell biology. Additionally, we performed in vitro validation of one of the identified variants. Results: We identified variants in the INHA, HIF1A, JAK2, DNM2, POSTN, ANGPTL4, FOXO1 and SMAD6 genes as putative drivers in HHT. We have identified the SMAD6 p.(Glu407Lys) variant in one of the families; this is a loss-of-function variant leading to the activation of the BMP/TGFβ signaling in endothelial cells. Conclusions: Variants in these genes should be considered for genetic testing in patients with HHT phenotype and negative for ACVRL1/ENG mutations.